Does Aggressive management with early high dose aspirin reduce the hypercoagulability of platelets following coronary artery bypass grafting?
- Conditions
- Aspirin is an antiplatelet drug that affects the ability of platelets in the blood to bind together and form clots. It is used routinely in patients with or at risk of heart disease and after surgery to bypass blocked arteries supplying the heart (coronary artery bypass graft, CABG, surgery). Following CABG surgery aspirin is used to reduce the progression of fatty deposits in the arteries to the heart to help prevent bypass grafts from blocking and improve patient survival.
- Registration Number
- EUCTR2006-000024-13-GB
- Lead Sponsor
- Cardiff and Vale NHS Trust
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Not specified
- Target Recruitment
- 120
Patients undergoing first time elective coronary artery bypass grafting only
Aspirin to be stopped for at least 5 days prior to surgery
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Patients with bleeding or platelet disorders
Re-do surgery
Age over 80 years
Emergency CABG for myocardial infarction
Off pump coronary artery bypass grafting
Patients stopping anti platelet therapy less then 5 days before the operation
Patient taking heparin / low-molecular heparin till the day of the operation
Patient stopping Warfarin less then 3 day before operation
Patients with a platelet count <150 x 103/ ml
Patients with Haematocrit < 35%
Bleeding disorders in early postoperative period
Patients with contraindications for aspirin
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method